{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-037376","form_type":"8-K","ticker":"BCYC","cik":"0001761612","company_name":"BICYCLE THERAPEUTICS PLC","filed_at":"2023-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.449583+00:00","generated_at":"2026-06-17T13:08:31.376188+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Bicycle Therapeutics enters Novartis collaboration for Bicycle radio-conjugates; $50M upfront, up to $1.7B milestones","bullets":["Bicycle Therapeutics receives $50M upfront from Novartis to discover Bicycle radio-conjugates for oncology targets.","Total potential milestones up to $1.7B, plus tiered royalties on commercial sales at high single to low double digits.","Novartis funds all preclinical/clinical development, manufacturing, and commercialization for BRCs.","Collaboration initially covers two targets; Novartis pays mid-teen million candidate selection fees per product."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-037376","json":"https://secwatch.observer/filing/0001104659-23-037376.json","markdown":"https://secwatch.observer/filing/0001104659-23-037376.md","text":"https://secwatch.observer/filing/0001104659-23-037376.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761612/000110465923037376/0001104659-23-037376-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761612/000110465923037376/tm2310706d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T13:08:31.376188+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f25ba5e4a218acd7fc23761aece3436d7b41935","claim":"BICYCLE THERAPEUTICS PLC entered into Collaboration Agreement with Novartis Pharma AG valued at $50 million (effective 2023-03-27).","evidence_excerpt":"On March 27, 2023, BicycleTx, Limited. (the “Company”) and Novartis Pharma AG (“Novartis”) entered into a collaboration and license agreement (the “Collaboration Agreement”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465923037376/0001104659-23-037376-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Novartis Pharma AG"},{"label":"Value","value":"$50 million"},{"label":"Effective","value":"2023-03-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}